Saturday, February 12, 2022 10:56:05 PM
HL,
Is it possible that DCVax-Prostate, Brain, Lung, etc. are all actually the same product, made from the Lysate of the cancer and in fact all can be defined by DCVax-L.
DCVax-Direct is different as it doesn't require the lysate from the tumor, it's injected into the tumor directly and creates the vaccine from within.
I know currently the intent is to use Direct on inoperable tumors, and that's the way the trials should be run. If in fact its benefits are seen in that venue, I question if it's use prior to surgery on operable tumors shouldn't be considered. As I see it, the biggest benefit of such treatment would be getting vaccine into the mets before the tumor is removed. It's the unseen and inoperable mets that later create new tumors. While creating DCVax-L from the tumor will certainly be of benefit, I would hope the benefit could be even greater if DCVax-Direct were injected some period of time before the tumor was surgically removed.
I could certainly be wrong about this if the presents of DCVax-Direct within the tumor detracted in some way from the Lysate used to create the DCVax-L. I welcome the thoughts of others on this matter.
Gary
Is it possible that DCVax-Prostate, Brain, Lung, etc. are all actually the same product, made from the Lysate of the cancer and in fact all can be defined by DCVax-L.
DCVax-Direct is different as it doesn't require the lysate from the tumor, it's injected into the tumor directly and creates the vaccine from within.
I know currently the intent is to use Direct on inoperable tumors, and that's the way the trials should be run. If in fact its benefits are seen in that venue, I question if it's use prior to surgery on operable tumors shouldn't be considered. As I see it, the biggest benefit of such treatment would be getting vaccine into the mets before the tumor is removed. It's the unseen and inoperable mets that later create new tumors. While creating DCVax-L from the tumor will certainly be of benefit, I would hope the benefit could be even greater if DCVax-Direct were injected some period of time before the tumor was surgically removed.
I could certainly be wrong about this if the presents of DCVax-Direct within the tumor detracted in some way from the Lysate used to create the DCVax-L. I welcome the thoughts of others on this matter.
Gary
Recent NWBO News
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 11/26/2025 05:15:34 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
